TSO3 Enters Into Strategic Partner Facility Agreement With Mount Sinai Hospital

TSO3 Inc., an innovator in sterilization technology for medical devices in healthcare settings, has entered into a strategic partner facility agreement with Mount Sinai Hospital of New York, N.Y.

Under the terms of the agreement, Mount Sinai Hospital and TSO3 have agreed to deploy TSO3's STERIZONE® VP4 Sterilizer technology and collaboratively share and evaluate related in-use technical and device reprocessing data.
   
"We are privileged to work closely with Mount Sinai as we continue the global deployment of our STERIZONE® VP4 Sterilizers," says Ric Rumble, TSO3's president and CEO. "We aim to further validate with Mount Sinai and other leading hospitals our ability to significantly improve existing sterilization processes, increase throughput and reduce cost, while exploring and assessing the process to enable routine terminal sterilization of multi-channel flexible endoscopes." 

The STERIZONE® VP4 Sterilizer is a low-temperature sterilization system that utilizes the dual-sterilants of vaporized hydrogen peroxide (H2O2) and ozone (O3) to achieve terminal sterilization of heat and moisture sensitive medical devices. Its single pre-programmed cycle can sterilize a large number and wide range of compatible devices, creating a cost-effective sterilization process with error free cycle selection. The device's unique Dynamic Sterilant Delivery System™ automatically adjusts the quantity of injected sterilant based on the load composition, weight and temperature. This capability removes the guesswork and potential for human error, as there is no need to sort instruments and choose the appropriate cycles as with other machines.

The STERIZONE® VP4 Sterilizer is the only terminal sterilization method that is FDA cleared to sterilize multi-channeled flexible endoscopes (with a maximum of four channels) of up to 3.5 meters in length, such as video colonoscopes and gastroscopes, an industry first for any medical device sterilization process.

Source: TSO3 Inc.